구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Darzalex (daratumumab) |
Overview Company | Janssen |
Overview Modality | ANTIBODY |
Overview Target | CD38 |
Overview Indication | Multiple myeloma |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Direct on-tumor + immunomodulatory effects |
Positioning Known limitation | CD38 downregulation, high tumor burden, and impaired effector function after prior lines. |
MoA Mechanism | Daratumumab binds CD38 on plasma cells and other immune cells, inducing direct apoptosis, Fc-mediated ADCC/CDC, and immunomodulatory effects including depletion of CD38+ regulatory cells and enhanced T-cell clonality. |
MoA Biomarker | CD38 expression on clonal plasma cells (universal in MM). |
PK/PD Half-life | 20 h |
PK/PD Species | Mouse, Human, M-protein, FLC, minimal residual disease, immunophenotypic CD38 saturation |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pd |
Toxicology Species | Cynomolgus monkey, Mouse, Human |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Infusion-related reactions (premedication required), cytopenias, and increased infection risk; subcutaneous formulation reduces IRR rate. |
Toxicology CRS | N/A |
Clinical Safety signal | Infusion-related reactions (premedication required), cytopenias, and increased infection risk; subcutaneous formulation reduces IRR rate. |
Clinical Selected reported efficacy | ORR 35.3% |
Clinical Reported ORR | 35.3% |
Clinical Result source | ClinicalTrials.gov NCT02990338 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02990338 |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Darzalex (daratumumab) |
Overview Company | Janssen |
Overview Modality | ANTIBODY |
Overview Target | CD38 |
Overview Indication | Multiple myeloma |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Direct on-tumor + immunomodulatory effects |
Positioning Known limitation | CD38 downregulation, high tumor burden, and impaired effector function after prior lines. |
MoA Mechanism | Daratumumab binds CD38 on plasma cells and other immune cells, inducing direct apoptosis, Fc-mediated ADCC/CDC, and immunomodulatory effects including depletion of CD38+ regulatory cells and enhanced T-cell clonality. |
MoA Biomarker | CD38 expression on clonal plasma cells (universal in MM). |
PK/PD Half-life | 20 h |
PK/PD Species | Mouse, Human, M-protein, FLC, minimal residual disease, immunophenotypic CD38 saturation |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pd |
Toxicology Species | Cynomolgus monkey, Mouse, Human |
Toxicology Animal (cat.) | NHP |
Toxicology Major finding | Infusion-related reactions (premedication required), cytopenias, and increased infection risk; subcutaneous formulation reduces IRR rate. |
Toxicology CRS | N/A |
Clinical Safety signal | Infusion-related reactions (premedication required), cytopenias, and increased infection risk; subcutaneous formulation reduces IRR rate. |
Clinical Selected reported efficacy | ORR 35.3% |
Clinical Reported ORR | 35.3% |
Clinical Result source | ClinicalTrials.gov NCT02990338 |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02990338 |
추천 비교
추천 비교